A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Trial With Extension Period to Evaluate the Efficacy and Safety of Xeomin® Injections for the Prevention of Chronic Migraine

In this clinical trial, participants with chronic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.
Trial details include:
* Trial duration: 52 to 55 weeks;
* Screening period: 4 to 5 weeks;
* Treatment duration: 4 treatments, each about 12 weeks apart; and
* Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.

Start Date01 Aug 2025

Sponsor / Collaborator

Merz Therapeutics GmbH

NCT07018700

/ RecruitingPhase 3

In this clinical trial, participants with episodic migraine will receive injections with Xeomin or Placebo into muscles of the head and neck. The purpose is to measure the change in monthly migraine days with Xeomin injections compared to Placebo injections.
Trial details include:
* Trial duration: 52 to 55 weeks;
* Screening period: 4 to 5 weeks;
* Treatment duration: 4 treatments, each about 12 weeks apart; and
* Visit frequency: about every 4 weeks, 14 visits in total. The first and last visit and the 4 treatment visits are on-site, the other 8 visits are remote by phone / video call.

Start Date01 Aug 2025

Sponsor / Collaborator

Merz Therapeutics GmbH

NCT06995287

/ Not yet recruitingPhase 3IIT

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea: a Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study

The objective of the study is to evaluate the global impression of improvement at 3 months following intramyometrial botulinum toxin injections via hysteroscopy in women with severe primary dysmenorrhea who have failed first-line medical treatment, compared to intramyometrial placebo injections.

Start Date01 Jun 2025

Sponsor / Collaborator

Nantes University Hospital

[+1]

100 Clinical Results associated with Incobotulinum toxinA (Biotecon)

100 Translational Medicine associated with Incobotulinum toxinA (Biotecon)

100 Patents (Medical) associated with Incobotulinum toxinA (Biotecon)

757

Literatures (Medical) associated with Incobotulinum toxinA (Biotecon)

01 Dec 2025·Techniques in Coloproctology

Urge fecal incontinence: are intramural rectal injections of botulinum toxin a long-term treatment option?

Article

Author: Baumstarck, Karine ; Vitton, Véronique ; Onana Ndong, Philippe

BACKGROUND AND AIMS:

Unsuccessful first-line conservative treatments for managing fecal incontinence (FI) lead to considering predominantly invasive options, posing challenges in terms of cost and patient acceptance of benefit/risk ratio. Recent data from a prospective randomized study have highlighted intramural rectal botulinum toxin (BoNT/A) injection as a promising minimally invasive alternative for urge FI, demonstrating efficacy at 3 months but lacking long-term evidence. This study aimed to evaluate the sustained efficacy and injection frequency of intramural rectal BoNT/A injection in the treatment of urge FI.

METHODS:

This retrospective monocentric study enrolled all patients who underwent intramural rectal BoNT/A injection for urge FI after failed conservative therapy or sacral neuromodulation (SNM). Injections were administered during sigmoidoscopy, delivering 200 U of BoNT/A at 10 circumferentially distributed sites. Treatment effectiveness was assessed using the Cleveland clinic incontinence score (CCS) and a visual analog scale (VAS) to measure the severity of discomfort related to episodes of fecal urgency, with reinjection performed upon symptom recurrence.

RESULTS:

In total, 41 patients (34 females) were included, with a median follow-up of 24.9 (range 3.2-70.3) months. Overall, 11 patients had previously failed sacral nerve stimulation. Significant reductions were observed in the CCS (median 11 versus 7, p = 0.001) and VAS symptoms (median 4, range 0-5 versus median 2, range 0-5, p = 0.001). In total, 22 patients (53%) experienced a reduction in the CCS by over 50%. The median interval between intramural rectal BoNT/A injections was 9.8 months (range 5.3-47.9 months).

CONCLUSIONS:

This study provides the first evidence of the sustained efficacy of intramural rectal BoNT/A injection for urge FI. Further investigations are warranted to refine patient selection and reinjection criteria, evaluate socioeconomic impacts, and compare rectal BoNT/A injection with other therapeutic modalities.

01 Aug 2025·EUROPEAN JOURNAL OF NEUROLOGY

Systematic Review and Meta-Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications.

Review

Author: Albrecht, Phillipp ; Carr, Warner ; Walter, Uwe ; Hefter, Harald

BACKGROUND:

Botulinum neurotoxin A (BoNT-A) is recommended for the treatment of cervical dystonia (CD), spasticity, and blepharospasm. Some patients treated with BoNT-A have been reported to develop neutralizing antibodies (NAbs) against BoNT-A, which may result in reduced efficacy and, in some cases, secondary treatment failure (STF). Our aim was to investigate the incidence of STF and NAb positivity after treatment with one of three commercially-available BoNT-A formulations.

METHODS:

A systematic review and meta-analysis of STF and/or NAb positivity after treatment with abobotulinumtoxinA, incobotulinumtoxinA, or onabotulinumtoxinA in patients with CD, spasticity, or blepharospasm was conducted using PubMed, Embase, and Google Scholar.

RESULTS:

Twenty-nine unique studies reported in 29 publications assessed NAb positivity and were included. The meta-analysis showed that the proportions of patients developing STF were significantly higher after treatment with abobotulinumtoxinA or onabotulinumtoxinA than with incobotulinumtoxinA for CD or spasticity. Depending on the antibody test used, the proportions of patients developing NAbs were also significantly higher after treatment with abobotulinumtoxinA or onabotulinumtoxinA than with incobotulinumtoxinA for CD or spasticity. When data for all indications were pooled, proportions of NAb-positive patients were numerically higher with increasing mean doses of abobotulinumtoxinA or onabotulinumtoxinA. No patients treated exclusively with incobotulinumtoxinA were found to have developed immunogenic STF or persistent NAbs.

CONCLUSIONS:

The risk of developing STF and NAbs appears to vary with indication and BoNT-A formulation. When the efficacy and safety of formulations are comparable, incobotulinumtoxinA may be recommended to avoid developing STF and immunogenicity, particularly for patients requiring higher doses and repeated treatments.

01 Jul 2025·CLINICAL NEUROLOGY AND NEUROSURGERY

The use of onabotulinum toxin type A and other neurotoxins for the treatment of chronic migraine: An American Headache Society survey study

Article

Author: Mathew, Paul G ; Hamilton, Kendra ; Ali, Ashhar ; Agarwal, Utkarsh

PURPOSE:

OnabotA is the only US Food and Drug Administration-approved neurotoxin for chronic migraine prevention; however, non-onabotA toxins may be equally effective. Few studies have explored clinician practices and patient outcomes with non-onabotA neurotoxins. Our study aimed to generate a statistical snapshot of clinician perspectives and treatment practices regarding onabotulinum toxin A (onabotA) and other neurotoxins for chronic migraine and comorbid conditions.

METHODS:

A 15-question survey was distributed online to clinician members of the American Headache Society (AHS) assessing clinical practices using onabotA and non-onabotA toxins for chronic migraine and comorbid conditions, and descriptive analysis was performed.

RESULTS:

168 respondents (162 from the United States and 6 from Canada) completed the survey (response rate 10.1 % [168/1665]). Of 48 respondents (28 % of total) using non-onabotA toxins for chronic migraine, 27 (16 %) used incobotulinum toxin A; 23 (14 %) used abobotulinum toxin A; and 12 (7 %) used rimabotulinum toxin B. Non-onabotA toxins were predominantly used due to administration/payor imposed issues (19/48; 40 %) and cost (18/48 [38 %]). Most clinicians using non-onabotA toxins reported similar efficacy to onabotA (32/48; 67 %), while fewer reported better efficacy (9/48 [19 %]) or worse efficacy (7/48 [15 %]) than onabotA. Many respondents (114/168 [68 %]) had used neurotoxins for chronic migraine in addition to other comorbid conditions, including temporomandibular joint disorders (95/114 [83 %]) and cervical dystonia (64/114 [56 %]).

CONCLUSION:

While non-onabotA toxins are used less frequently for chronic migraine, they may have similar efficacy as onabotA and are used off-label in clinical practice due to administrative/payor issues or cost.

News (Medical) associated with Incobotulinum toxinA (Biotecon)

07 Aug 2025

·www.einpresswire.com

DermAlign Medical Aesthetics Removes Wrinkles with Ease

DermAlign Medical Aesthetics now uses this minimally non-surgical cosmetic treatment called PDO Thread Lift as an alternative to the standard Surgical Facelift. LANGHORNE , PA, UNITED STATES, August 7, 2025 / EINPresswire.com / -- DermAlign Medical Aesthetics Removes Wrinkles with Ease August 7, 2025 DermAlign Medical Aesthetics based in Langhorne, Pa, would like to reach out to residents who may be in search of anti-aging medical spa treatments. This Med Spa offers a wide range of medical spa treatments with a special emphasis on wrinkle removal techniques. DermAlign Medical Aesthetics is a boutique med spa committed to providing exceptional cosmetic care using the latest non-surgical technologies. With a strong emphasis on natural beauty, safety, and personalized service, so whether you’re looking for Injectables, Micro-Needling, PDO Thread Lifting, Sexual Wellness, Medical Grade Weight Loss, Hair Restoration, PRP or the latest Hollywood Salmon Sperm PDRN DermAlign Medical Aesthetics has you covered. The Medical Staff at DermAlign Medical Aesthetics invests in over 100 Continuing Education hours per year ensuring that their patients receive the most advance & update treatments and thus allowing DermAlign Medical Aesthetic to be a leader in medical aesthetics field. Ekata Rushi PA-C, Founder of DermAlign Medical Aesthetics looks forward to providing quality, effective treatments to her patients. While DermAlign Medical Aesthetics mainly services the Mainline, Bryn Mawar, Bluebell, King of Prussia, New Hope, Bucks, Montgomery County PA. & Mercer & Hunterdon County NJ. “Men and women throughout the country as far as Alabama to Miami Fl. fly in to see Ekata Rushi PA-C. Patients can finally look and feel their best with the help of DermAlign Medical Aesthetics. Ekata Rushi PA-C at DermAlign Medical Aesthetics is a leading Aesthetic Medicine Physician Associate who offers her patients the latest in Wellness and Aesthetic solutions. Ekata specializes in the “30 minute nonsurgical face lift” using PDO Threads. Using the most advance Facelift techniques that she learned from the world leading plastic surgeons. So even if you’re looking for the best wrinkle removal treatments, DermAlign Med Spa utilizes many non-invasive techniques and treatments that can help remove wrinkles from the faces of our patients. One very popular option that is offered at the Med spa is the insertion of dermal fillers, which can help smooth out one’s skin and minimize the appearance of moderate to deep grooves and wrinkles. The spa uses clinically tested and proven dermal fillers from dependable producers like JUVÉDERM ® to fill in areas where the patient may have lost volume. The advanced dermal fillers used by Ekata Rushi PA-C are made to last a long time, and one can expect the effects to last up to years. While dermal fillers can boost the appearance of one’s skin on an immediate basis, it is still important to take care of one’s skin and protect it in order to lessen the effects of aging. DermAlign Medical Aesthetics offers its own Medical Grade Skin line solutions to help patients maintain the appearance of their skin. Ekata Rushi PA-C also offers her patients advice on how to avoid wrinkles. “Once Ekata Rushi PA-C gets you started on your custom anti-aging regimen you will begin to notice the benefits of injectables and Medical grade Skin products, you need to start looking at preventive skincare,” says Ekata. “Granted, you’re still going to age, so you can’t stop all wrinkles from forming. However, you can certainly work to lessen your risk of deep wrinkles and other signs of aging. The best way to prevent wrinkles is to minimize sun exposure and wear sunscreen daily. DermAlign Medical Aesthetics has an entire line of protective products that offer SPF protection. Some products are even tinted and blend in perfectly underneath your makeup. Schedule your anti-aging consultation at DermAlign Medical Aesthetics and take control of your wrinkles.” Ekata Rushi PA-C has over 14 years of Neurosurgical & Weight loss surgical and Emergency Medicine Experience. After over a decade of high-intensity medical & surgical care, she turned her attention to aesthetics, pursuing her passion for artistry and long-term patient care. Ekata lives in Newtown with her husband and two daughters and is deeply involved in the local community. At DermAlign, her mission is simple: to educate, empower, and enhance every patient’s natural beauty with safe, effective, and proven treatments. and is considered a leader in the cosmetic medicine industry. A number of Ekata patients have left excellent reviews of her work. One review on the DermAlign Medical Aesthetics GMB listing, from a patient named Edina “Omg I can’t say enough she is absolutely wonderful, check out my before and after pictures- also she called me in the evening and left me message to remind me of the aftercare needed, and the next day also to see how I was doing, you do not find anyone who will care enough to call and check on you anywhere !!! She is an amazing artist with her work; I will definitely be back also check her out on Instagram! " Another patient, Melissa “New Botox/Xeomin patient appointment today. The staff was very friendly & knowledgeable. Took their time to explain everything in detail. Didn’t feel rushed. I definitely will be returning.” Contact Information • DermAlign Medical Aesthetics • 320 Middletown Blvd, Ste 300, Langhorne, PA 19047, USA • info@dermalignmedspa.com • www.Dermalignmedspa.com EKATA RUSHI PA-C DERMALIGN MEDICAL ANESTHETICS INFO@DERMALIGNMEDSPA.COM Visit us on social media: Instagram Facebook YouTube TikTok Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

18 Dec 2024

·www.prnewswire.com

Persimmon.life Introduces SmartTox® Injectable Treatment Offered at Select Massage Envy Locations

Persimmon.life will provide their medical aesthetic services at select Massage Envy Franchised locations across Arizona and California in early 2025 SCOTTSDALE, Ariz., Dec. 18, 2024 /PRNewswire/ -- Massage Envy, a national leader in skin care and the nation's No. 1 provider of massage in the U.S. collectively across its franchise network, and Persimmon.life, the leader in on-location medical aesthetic treatments, today announced a new initiative in which Persimmon will offer SmartTox® injectable treatments at select Massage Envy franchised locations across Arizona and California in early 2025. "Massage Envy is always looking for strategic relationships with brands that help address consumers' wellness goals. Persimmon's use of Massage Envy locations to provide their medical aesthetic services will not only be convenient, but will also address the needs of the modern skincare consumer," said Todd Schrader, CEO, Massage Envy Franchising. "Massage Envy has been a leader in skin care for over 16 years and looking and feeling your best is at the core of the Massage Envy brand. We are excited that our franchisees are welcoming Persimmon into their Massage Envy franchised locations." Each Persimmon service includes a personalized assessment with a Persimmon Provider, who will review goals, answer questions and explain the treatment. Sessions typically take between 15 and 20 minutes. "Massage Envy is a company that has set the standard for accessible wellness and self-care," said Mark Hadfield, CEO, Persimmon.life. "At Persimmon, we share Massage Envy's commitment to helping people look and feel their best, and we're thrilled that Persimmon will be on-site at select Massage Envy franchised locations to provide high-quality, medically-driven SmartTox® treatments." According to Persimmon.life, SmartTox®, also known as XEOMIN® and IncobotulinumtoxinA or Neurotoxin, is a double-filtered neuromodulator injection that smooths upper facial lines including frown lines, forehead lines and crow's feet without unnecessary proteins. The procedure will be available by appointment only at select Massage Envy California and Arizona franchise locations beginning in early 2025. For more information and to make an appointment, visit the Persimmon website at . About Persimmon Founded in 2021, Persimmon is at the forefront of medical aesthetics, transforming how aesthetic treatments are provided. By partnering with local businesses, Persimmon offers clients unparalleled flexibility and privacy through a growing network of highly skilled, medically-trained injection nurses available at select partnership locations. Guided by a clinical leadership team of expert nurses, Persimmon has established itself as a leader in safety, quality, and care. Their meticulously-designed training and treatment protocols ensure every client experiences top-tier results. With thousands of glowing five-star reviews, Persimmon's reputation speaks to its commitment to excellence and its ability to deliver transformative care in a setting that clients trust and enjoy. For more information, visit or follow @persimmon.life on Instagram, TikTok and Facebook. About Massage Envy Massage Envy, based in Scottsdale, Arizona, is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services and skin care offerings. Massage Envy was founded in 2002 and started offering skin care services in 2008. The brand now has over 1,000 franchise locations in 49 states that have together delivered more than 225 million massages and skin care services. For more information, visit or follow @MassageEnvy on Instagram, X and Facebook. Contact: [email protected] SOURCE Massage Envy WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

17 Dec 2024

·www.businesswire.com

Health Canada Approves XEOMIN® (incobotulinumtoxinA) for Treatment of Adults with Post-stroke Lower Limb Spasticity in the Ankle and Foot

BURLINGTON, Ontario--( BUSINESS WIRE )-- Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ® (incobotulinumtoxinA) for the treatment of post-stroke lower limb spasticity involving the ankle and foot in adults. “This approval means that adult patients who have suffered from a stroke and are experiencing lower limb spasticity in the ankle and foot will now have a safe and effective treatment option,” explains Michael Stone, Country Manager, Canada for Merz Therapeutics. “With this label extension, healthcare providers can now utilize XEOMIN to pursue more comprehensive and individually ambitious treatment goals for their patients.” Addressing multiple patterns of spasticity with XEOMIN Strokes are the primary cause of spasticity resulting from damage to the upper motor neuron, producing an abnormal increase in muscle tone. In Canada, 109,000 people annually suffer a stroke 1 , and 25% to 43% of stroke survivors experience spasticity within a year 2 . XEOMIN with the active ingredient incobotulinumtoxinA is injected intramuscularly to reduce the abnormally increased muscle tone. With the new approval, XEOMIN can be administered in up to 600 units for upper and lower limbs combined, enabling qualified healthcare professionals in Canada to treat both regions together or individually, adjusting the dosage depending on patient requirements and mobility goals. The safety findings were similar to previous adult studies and in line with the known safety profile of XEOMIN. The most common adverse reactions affecting ≥1% of patients were nasopharyngitis, pharyngitis, tinea pedis, muscular weakness, epilepsy, fall, eczema, dehydration, and blurred vision. “Foot and ankle spasticity are the most common posture problems seen in the lower limb in adult patients following a stroke. They typically present with an equinovarus deformity, which refers to the foot turning downwards and inwards in these limbs," said Professor Lalith Satkunam, Glenrose Rehabilitation Hospital, Edmonton, Alberta. "Lower limb spasticity can limit ambulation and impede on patients' daily lives, so this latest approval for XEOMIN provides healthcare professionals, like me, the ability to comprehensively treat multiple areas of spasticity.” “The ability to simultaneously treat both upper and lower limb post-stroke spasticity in adults with botulinum toxin using a combined total dose of 600 units makes it an essential tool in our treatment arsenal,” shared Dr. Jehane Dagher, Institut de réadaptation Gingras-Lindsay-de-Montréal (IRGLM), Montreal, Quebec. A label extension built on solid data Canada is the third country to authorize XEOMIN for lower limb treatment based on data from a Japanese study (J-PLUS), which investigated the effects of XEOMIN on spasticity in Japanese stroke survivors. “Health Canada’s decision to extend XEOMIN’s area of application once again underlines the quality and robustness of our Japanese data and is a testament to our conviction that delivering better outcomes for more patients must be an international effort,” says Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “We were able to extrapolate the clinical data generated in Japan to support the application with Health Canada based on a larger dataset from multiple clinical trials and decisive efficacy data from a Japanese study.” Previously, data from J-PLUS had also been included in application packages for label extensions for lower limb treatment in the United Kingdom and Switzerland. This is the sixth therapeutic indication for XEOMIN in Canada, which was first licensed by Health Canada in 2009 for the treatment hypertonicity disorders of the seventh nerve such as blepharospasm, including benign essential blepharospasm and hemifacial spasm in adults, to reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults, and for the treatment of upper limb spasticity in adults. 3 XEOMIN was also licensed for adult patients with chronic sialorrhea in 2020 and for pediatric patients (age 2-17 years weighing 12 kg or more) in 2022. References 1. Holodinsky JK, Lindsay P, Yu AYX, Ganesh A, Joundi RA, Hill MD. Estimating the Number of Hospital or Emergency Department Presentations for Stroke in Canada. Can J Neurol Sci . 2023;50(6):820-825. doi:10.1017/cjn.2022.338 2. Effects of Stroke, Phyiscal Effects, Spasticity . 30 May 2023, www.stroke.org/en/about-stroke/effects-of-stroke/physical-effects/spasticity . Accessed 4 Nov. 2024. 3. XEOMIN ® Product Monograph. Merz Pharma Canada Ltd. December 11, 2024. About XEOMIN ® XEOMIN ® (incobotulinumtoxinA) is a prescription medicine that is injected into muscles or glands and used to treat adults and pediatric patients with chronic drooling (sialorrhea), eyelid spasm (blepharospasm) and spasm in one side of the face (hemifacial spasm), twisted neck (spasmodic torticollis), spasticity of the upper limb in adults and post-stroke lower limb spasticity involving the ankle and foot in adults. Copyright © 2024 Merz Pharma Canada Ltd. All rights reserved. MERZ, the MERZ logo, and XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KGaA. For more information, please see the XEOMIN ® full Product Monograph . About Merz Therapeutics Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a Canada affiliate based in Burlington, Ontario, Canada. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 116 years to developing innovations that serve unmet patient and customer needs. Please visit www.merztherapeutics.com About Merz Merz Group is a global, diversified company in the healthcare sector based in Frankfurt, Germany. Family-owned for over 116 years, the company is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 4,337 people (as of the 22/23 financial year) in 28 countries worldwide. To learn more, please visit www.merz.com .

Drug Approval

100 Deals associated with Incobotulinum toxinA (Biotecon)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Incobotulinum toxinA (Biotecon)	M03AX01	DB00083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
cervical dystonia	Australia	Merz Australia Pty Ltd	28 Nov 2023
Crow's feet	Australia	Merz Australia Pty Ltd	28 Nov 2023
Forehead lines	Australia	Merz Australia Pty Ltd	28 Nov 2023
Lower limb spasticity	Japan	Teijin Pharma Ltd.	29 Jun 2020
Upper limb spasticity	Japan	Teijin Pharma Ltd.	29 Jun 2020
Limb spasticity	United States	Merz Pharmaceuticals LLC	22 Dec 2015
Glabellar frown lines	United States	Merz Pharmaceuticals LLC	20 Jul 2011
Blepharospasm	United States	Merz Pharmaceuticals LLC	30 Jul 2010
Torticollis	United States	Merz Pharmaceuticals LLC	30 Jul 2010
Sialorrhea	Austria	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Belgium	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Bulgaria	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Croatia	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Cyprus	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Czechia	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Denmark	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Estonia	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Finland	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	France	Merz Pharmaceuticals GmbH	24 Oct 2007
Sialorrhea	Germany	Merz Pharmaceuticals GmbH	24 Oct 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platysma Prominence	Phase 3	-	Merz Aesthetics, Inc.	01 Aug 2025
Chronic pelvic pain syndrome	Phase 3	France	Merz Pharmaceuticals GmbH	01 Jun 2025
Primary dysmenorrhea	Phase 3	France	Merz Pharmaceuticals GmbH	01 Jun 2025
Atrial Fibrillation	Phase 3	France	Merz Pharmaceuticals GmbH	30 Sep 2019
Intellectual Disability	Phase 3	Georgia	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	Hungary	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	Poland	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	Russia	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	Serbia	Merz Pharmaceuticals GmbH	09 Feb 2015
Intellectual Disability	Phase 3	Ukraine	Merz Pharmaceuticals GmbH	09 Feb 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04965311 (CTgov)	Phase 2	Pancreatic Fistula \| Pancreatic Cancer	4	Botulinum Toxin Type A	hebyoznijt = flivjwlbmh jwppxsjthc (qwxxueujlc, uzzplnfwve - cbkjqeotpi) View more	-	13 May 2025
NCT04622254 (ULTRA II, CTgov)	Phase 3	-	368	Placebo (Main Period: Placebo (Group P))	ddsqmhainx = svmiztngdn gmrmoabhkr (ojfakorvdi, ocdntkzgrv - idtducfbfs) View more	-	06 Aug 2024
				NT 201 (Main Period: NT 201 (Group U))	ddsqmhainx = oxvbgfuhdr gmrmoabhkr (ojfakorvdi, pwmdzlbmvn - vlxytemfuq) View more
NCT04594213 (ULTRA I, CTgov)	Phase 3	-	362	Placebo (Main Period: Placebo (Group P))	azaplusiti = qetailhlua woitnwggai (fyllokcxlk, vdupqscpxs - kqytcllebm) View more	-	08 May 2024
				NT 201 (Main Period: NT 201 (Group U))	azaplusiti = wapzvdtqae woitnwggai (fyllokcxlk, jhwffkkail - avmevlifkd) View more
P8-3.004 (AAN2024)	Not Applicable	cervical dystonia	451	IncobotulinumtoxinA	inujumohxs(pauhftnfxk) = xjekltqijg qwhyknmuta (tnpzavczpk ) View more	Positive	09 Apr 2024
				Placebo	inujumohxs(pauhftnfxk) = sbvsmwislc qwhyknmuta (tnpzavczpk ) View more
NCT03806933 (CTgov)	Phase 2	-	241	MP+NT 201 (Stage 1 and 2 Pooled: NT 201 20 U)	hfaphyejfs(uvnxerrxus) = qtqmjzkqmt duxiumkbxf (ihreoulsxm, xyzpuqlrze - kivbypcgii) View more	-	04 Oct 2023
				MP+NT 201 (NT 201 50 U)	hfaphyejfs(uvnxerrxus) = jwwbccekxp duxiumkbxf (ihreoulsxm, vffcigceoi - mdjxfgiudb) View more
MDS2023	Not Applicable	-	451	IncobotulinumtoxinA	lxlnvtjmjw(xxnenjpirv) = xpwfzggvls uxkmonlpci (mlkdpcoaye )	-	27 Aug 2023
				Placebo	lxlnvtjmjw(xxnenjpirv) = bqgdykbzif uxkmonlpci (mlkdpcoaye )
NCT02088632 (CTgov)	Phase 2	Trigeminal Neuralgia	6	Incobotulinumtoxina (Incobotulinumtoxina)	ruzzwxbcso(hmemsuucxe) = qpzysqmkac cbobhejiiq (vloyzfcriq, smnkdnbhnf - jjpesytkdk) View more	-	28 Jun 2023
				Placebo Comparator (Placebo Comparator)	ruzzwxbcso(hmemsuucxe) = wxrkoncmaj cbobhejiiq (vloyzfcriq, jkromhnsny - tfyskijgnt) View more
P14-11.008 (AAN2023)	Phase 2/3	Limb spasticity	542	IncobotulinumtoxinA	ogahudljeb(ehngrwbpfp) = ethmxjycrl oorslxdqco (hdkezoitod ) View more	Positive	25 Apr 2023
				Placebo	ogahudljeb(ehngrwbpfp) = haxgktjpcg oorslxdqco (hdkezoitod ) View more
P12-11.009 (AAN2023)	Phase 2/3	Limb spasticity	515	incoA injections	xlnbygtroi(rzlrzrzgku) = tjreqjuqlp kzmnxkhagg (bsvusvnfzn ) View more	-	25 Apr 2023
NCT04148872 (CTgov)	Phase 4	Facial Paralysis \| Synkinesis	15	Neuromuscular Retraining + Chemodenervation (Neuromuscular Retraining Therapy)	bkahhdvzrx(gggackumku) = flufwyndoe lexgswuzos (fpqucpwpwj, 4.72) View more	-	29 Sep 2022
				Chemodenervation (4 months) (Chemodenervation)	bkahhdvzrx(gggackumku) = dvxakmofwm lexgswuzos (fpqucpwpwj, 3.72) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis